Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome - PubMed (original) (raw)

Review

Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome

Laura Amato et al. Cochrane Database Syst Rev. 2011.

Abstract

Background: Alcohol abuse and dependence represents a very serious health problem worldwide with major social, interpersonal and legal interpolations. Pharmacological treatments presently used are of uncertain effectiveness and there is even more doubt on the comparative effects and value for money.

Objectives: To summarize Cochrane reviews that assess the effectiveness and safety of pharmacological interventions in the treatment of alcohol withdrawal.

Methods: We searched the Cochrane Database of Systematic Reviews (30 November 2010). Two authors independently screened, extracted data, summarised key characteristics of the included reviews and assessed their quality using AMSTAR; the quality of the evidence was summarised according to the GRADE methodology.

Main results: Five reviews, 114 studies, 7333 participants, satisfied criteria for inclusions. The outcomes considered were alcohol withdrawal seizures, adverse events and dropouts. Comparing the five treatments with placebo, benzodiazepines performed better for seizures, three studies, 324 participants, RR 0.16 (95% CI 0.04 to 0.69), moderate quality of evidence. Comparing each of the five treatments versus specific class of drugs, benzodiazepines performed better than antipsychotics for seizures, 4 studies, 633 participants, RR 0.24 (95% CI 0.07 to 0.88) high quality of the evidence. Comparing different benzodiazepines and anticonvulsants among themselves, 28 comparisons, results never reached statistical significance but chlordiazepoxide performed better. The quality of evidence was high for 3% of the results, moderate for 28%, low for 48% and very low for 20%.

Authors' conclusions: Among the treatments considered, benzodiazepines showed a protective benefit against seizures, when compared to placebo and a potentially protective benefit for many outcomes when compared with antipsychotics. Nevertheless, no definite conclusions about the effectiveness and safety of benzodiazepines were possible, because of the heterogeneity of the trials both in interventions and in the assessment of outcomes. Data on potential harms are sparse and fragmented. Results do not provide sufficient evidence in favour of anticonvulsants for the treatment of AWS, but anticonvulsants seem to have limited side effects. There is also not enough evidence of effectiveness and safety of baclofen, because only one study consider this treatment and of GHB for which no strong differences were observed in the comparisons with placebo, benzodiazepines and anticonvulsants.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1

Flow chart of reviews

2

Summary of findings table: treatments versus placebo

3

Tratments versus specific class of drugs

Update of

• doi: 10.1002/14651858.CD008537

Similar articles

• Benzodiazepines for alcohol withdrawal.
  Amato L, Minozzi S, Vecchi S, Davoli M. Amato L, et al. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005063. doi: 10.1002/14651858.CD005063.pub3. Cochrane Database Syst Rev. 2010. PMID: 20238336 Review.
• Anticonvulsants for alcohol withdrawal.
  Minozzi S, Amato L, Vecchi S, Davoli M. Minozzi S, et al. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005064. doi: 10.1002/14651858.CD005064.pub3. Cochrane Database Syst Rev. 2010. PMID: 20238337 Review.
• Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.
  Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Leone MA, et al. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006266. doi: 10.1002/14651858.CD006266.pub2. Cochrane Database Syst Rev. 2010. PMID: 20166080 Review.
• Benzodiazepines for alcohol withdrawal.
  Ntais C, Pakos E, Kyzas P, Ioannidis JP. Ntais C, et al. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005063. doi: 10.1002/14651858.CD005063.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034964 Updated. Review.
• Anticonvulsants for alcohol withdrawal.
  Polycarpou A, Papanikolaou P, Ioannidis JP, Contopoulos-Ioannidis DG. Polycarpou A, et al. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005064. doi: 10.1002/14651858.CD005064.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034965 Updated. Review.

Cited by

• Severe alcohol withdrawal during pregnancy or early postpartum: maternal and fetal outcomes.
  Daidone S, Unlu H, Yehia A, Zhang N, Abulseoud OA. Daidone S, et al. Arch Womens Ment Health. 2024 Nov 11. doi: 10.1007/s00737-024-01531-4. Online ahead of print. Arch Womens Ment Health. 2024. PMID: 39523242
• Pharmacologic Management of End-of-Life Delirium: Translating Evidence into Practice.
  Hui D, Cheng SY, Paiva CE. Hui D, et al. Cancers (Basel). 2024 May 28;16(11):2045. doi: 10.3390/cancers16112045. Cancers (Basel). 2024. PMID: 38893163 Free PMC article. Review.
• Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy.
  Minozzi S, Ambrosi L, Saulle R, Uhm SS, Terplan M, Sinclair JM, Agabio R. Minozzi S, et al. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD015042. doi: 10.1002/14651858.CD015042.pub2. Cochrane Database Syst Rev. 2024. PMID: 38682758
• Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease.
  Ratner JA, Blaney H, Rastegar DA. Ratner JA, et al. Hepatol Commun. 2024 Jan 22;8(2):e0372. doi: 10.1097/HC9.0000000000000372. eCollection 2024 Feb 1. Hepatol Commun. 2024. PMID: 38251886 Free PMC article.
• ACG Clinical Guideline: Alcohol-Associated Liver Disease.
  Jophlin LL, Singal AK, Bataller R, Wong RJ, Sauer BG, Terrault NA, Shah VH. Jophlin LL, et al. Am J Gastroenterol. 2024 Jan 1;119(1):30-54. doi: 10.14309/ajg.0000000000002572. Epub 2023 Sep 1. Am J Gastroenterol. 2024. PMID: 38174913

References

References to included reviews

Amato 2010

1. 1. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD005063.pub3] - DOI - PubMed

Gillman 2007

1. 1. Gillman MA, Lichtigfeld F, Young T. Psychotropic analgesic nitrous oxide for alcoholic withdrawal states. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD005190.pub2] - DOI - PubMed

Leone 2010

1. 1. Leone MA, Vigna‐Taglianti F, Avanzi G, Brambilla R, Faggiano F. Gamma‐hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD006266.pub2] - DOI - PubMed

Liu 2011

1. 1. Liu J, Wang L. Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008502] - DOI - PubMed

Minozzi 2010

1. 1. Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database of Systematic Reviews 2010, Issue 2. [DOI: 10.1002/14651858.CD005064.pub2] - DOI - PubMed

References to excluded reviews

Fox 2003

1. 1. Fox C, Loughlin P, Cook C. Disulfiram for alcohol dependence. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD004331] - DOI

Pani 2010

1. 1. Pani PP, Trogu E, Amato L, Davoli M. Antidepressants for the treatment of depression in alcohol dependent individuals. Cochrane Database of Systematic Reviews 2010, Issue 7. [DOI: 10.1002/14651858.CD008581] - DOI

Roessner 2010a

1. 1. Rösner S, Hackl‐Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for Alcohol Dependence. Cochrane Database of Systematic Reviews 2010, Issue 9. [DOI: 10.1002/14651858.CD004332] - DOI - PubMed

Roessner 2010b

1. 1. Rösner S, Hackl‐Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD001867.pub2] - DOI - PubMed

Smith 2009

1. 1. Smith EJ, Lui S, Terplan M. Pharmacologic Interventions for Pregnant Women Enrolled in Alcohol Treatment. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007361.pub2] - DOI - PMC - PubMed

Additional references

Atkins 2004

1. 1. Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490‐4. - PMC - PubMed

Choi 2005

1. 1. Choi EA, Ki SW, Kim SE, Kim JW, Park JK. The Efficacy and Safety of Topiramate in the Treatment of Alcohol Withdrawal. Korean Database 2005;44(3):328‐33.

Colombo 1995

1. 1. Colombo G, Agabio R, Lobina C, Reali R, Fadda F, Gessa GL. Symmetrical generalization between the discriminative stimulus effects of gamma‐hydroxybutyric acid and ethanol: occurrence within narrow dose ranges. Physiology & behavior 1995;57:105‐11. - PubMed

Colombo 1998

1. 1. Colombo G, Agabio R, Diaz G, Reali R, Gessa GL. Gammahydroxybutyricacid (GHB) intake in ethanol‐preferring (sP) and ‐non preferring (sNP) rats. Physiology & behavior 1998;64:197‐202. - PubMed

De Witte 2003

1. 1. Witte P, Pinto E, Ansseau M, Verbanck P. Alcohol and withdrawal: from animal research to clinical issues. Neuroscience and Biobehavioral Reviews 2003;27(3):189‐97. - PubMed

Dodd 2000

1. 1. Dodd PR, Beckmann AM, Davidson MS, Wilce PA. Glutamate‐mediated transmission, alcohol, and alcoholism. Neurochemistry International 2000;37(5‐6):509‐33. - PubMed

DSM‐IV‐R

1. 1. AA.VV. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition revised.Washington, DC. American Psychiatric Association (Pub), 1995.

Frau 1995

1. 1. Frau M, Colombo G, Marchese G, Stefanini E, Gessa GL. Differentaffinity of cortical GHB binding site in Sardinian alcohol‐preferring (sP) and ‐non preferring (sNP) rats. Alcohol and Alcoholism 1995;30:133‐7. - PubMed

Gallimberti 1989

1. 1. Gallimberti L, Canton G, Gentile N, Ferri M, Cibin M, Ferrara SD, et al. Gamma‐hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lamcet 1989;2:787‐9. - PubMed

Gallimberti 1992

1. 1. Gallimberti L, Ferri M, Ferrara S, Fadda F, Gessa GL. Gammahydroxybutyricacid in the treatment of alcohol dependence: a double‐blind study.. Alcoholism, Clinical and Experimental Research 1992;16:673‐6. - PubMed

Gann 2004

1. 1. Gann H, Feige B, Cloot O, Wasen H, Zinzgraf D, Hohagen F, Riemann D. Polysomnography during withdrawal with chlormethiazole or placebo in alcohol dependent patients‐‐a double‐blind and randomised study . Pharmacopsychiatry 2004;37(5):228‐351. - PubMed

Gillman 1986

1. 1. Gillman MA. Minireview: Analgesic (sub anaesthetic) nitrous oxide interacts with the endogenous opioid system : A review of the evidence. Life Sciences 1986;39(14):1209‐21. - PubMed

Gillman 1996

1. 1. Gilman S, Koeppe RA, Junck L, Kluin KJ, Lohman M, Laurent RT. Benzodiazepine receptor binding in the cerebellum in multiple system atrophy and olivopontocerebellar atrophy studied with positron emission tomography. Advances in Neurology 1996;69:456‐66. - PubMed

Gillman 1998

1. 1. Gillman MA, Lichtigfeld FJ. Clinical role and mechanisms of action of analgesic nitrous oxide.. International Journal of Neuroscience 1998;93(1‐2):55‐62. - PubMed

Hasin 1990

1. 1. Hasin DS, Grant B, Endicott J. The natural history of alcohol abuse: implications for definitions of alcohol use disorders. The American Journal of Psychiatry 1990;147(11):1537‐41. - PubMed

Holbrook 1999

1. 1. Holbrook AM, Growther R, Lotter A, Cheng C, King D. Metaanalysis of benzodiazepine use in the treatment of acute alcohol withdrawal. Canadian Medical Association Journal 1999;282(11):1054‐60. - PMC - PubMed

Jadad 1998

1. 1. Jadad AR, Cook DJ, Jones A, Klassen TP, Tugwell P, Moher M, et al. Methodology and reports of systematic reviews and meta‐analyses:a comparison of Cochrane reviews with articles published in paper‐based journals. JAMA 1998;280(2):278‐80. - PubMed

Jermain 1992

1. 1. Jermain DM, Drismon ML, Nisbet RB. Controversies over the use of magnesium sulphate in delirium tremens. Annals of Pharmacotherapy 1992;26:650‐2. - PubMed

Koethe 2007

1. 1. Koethe D, Juelicher A, Nolden BM, Braunwarth WD, Klosterkotter J, Niklewski G, et al. Oxcarbazepine‐‐efficacy and tolerability during treatment of alcohol withdrawal: a double‐blind, randomised, placebo‐controlled multicenter pilot study. Alcoholism, Clinical and Experimental Research 2007;31(7):1188‐94. - PubMed

Kohl 1998

1. 1. Kohl RR, Katner JS, Chernet E, McBride WJ. Ethanol and negative feedback regulation of mesolimbic dopamine release in rats. Psychopharmacology 1998;139(1‐2):79‐85. - PubMed

Koob 1997

1. 1. Koob GF, Nestler EJ. The neurobiology of drug addiction. The Journal of Neuropsychiatry and Clinical Neurosciences 1997;9(3):482‐97. - PubMed

Leggio 2008

1. 1. Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non‐benzodiazepine GABAergic medications. Progress in neuro‐psychopharmacology & biological psychiatry 2008;32(5):1106‐7. - PubMed

Lejoyeux 1998

1. 1. Lejoyeux M, Solomon J, Adès J. Benzodiazepine treatment for alcohol dependent patients.. Alcohol and Alcoholism 1998;33:563‐75. - PubMed

Mayo‐Smith 1997

1. 1. Mayo‐Smith MF. Pharmacological management of alcohol withdrawal: a meta‐analysis and evidence‐based practice guideline.American Society of Addiction Medicine Working Group onPharmacological Management of Alcohol Withdrawal.. JAMA 1997;278(2):144‐51. - PubMed

McKay 2004

1. 1. McKay A, Koranda A, Axen D. Using a symptom‐triggered approach to manage patients in acute alcohol withdrawal.. Medical‐Surgical Nurses 2004;13(1):15‐20. - PubMed

Moher 2007

1. 1. Moher D, Tetzlaff J, Tricco AC, Sampson M, Altman DG. Epidemiology and reporting characteristics of systematic reviews. PLoS Medicine 2007;4(3):e78. - PMC - PubMed

Nutt 1999

1. 1. Nutt D. Alcohol and brain. Pharmacological insights for psychiatrists. The British Journal of Psychiatry 1999;175:114‐9. - PubMed

Petty 1993

1. 1. Petty F, Fulton M, Moeller FG, Kramer G, Wilson L, Fraser K, et al. Plasma gamma‐aminobutyric acid (GABA) is low in alcoholics. Psychopharmacology Bulletin 1993;29(2):277‐81. - PubMed

Shane 1991

1. 1. Shane SR, Flink EB. Magnesium deficiency in alcohol addiction and withdrawal. Magnesium and Trace Elements 1991;10:263‐8. - PubMed

Shea 2007

1. 1. Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, HamelC, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Medical Research Methodology 2007;15(7):10. - PMC - PubMed

SIGN 2003

1. 1. Scottish Intercollegiate Guidelines Network (SIGN). The management of harmful drinking and alcohol dependence in primary care. A national clinical guideline. www.sign.ac.uk 2003.

Slawecki 1999

1. 1. Slawecki CJ, Somes C, Ehlers CL. Effects of chronic ethanol exposure on neurophysiological responses to corticotropin‐releasing factor and neuropeptide Y. Alcohol and Alcoholism 1999;34(3):289‐99. - PubMed

Sullivan 1989

1. 1. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA‐Ar).. British Journal of Addiction 1989;84(11):1353‐7. - PubMed

Tsai 1995

1. 1. Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism.. The American Journal of Psychiatry 1995;152(3):332‐40. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Wiley

• Medical

  • MedlinePlus Health Information